Access all of the content
It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B.
Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at EASL ILC 2021, 23-26 June.
- What was the rationale for investigating antiviral treatments, such as tenofovir and entecavir, in the treatment of COVID-19 infection for those with chronic hepatitis B? (0:23)
- Could you briefly summarise the aims of your study, the methods used and the analysis performed? (1:00)
- What were the key clinical findings from the research? (2:23)
- Based on these findings, could tenofovir be providing a protective effect from severe COVID-19 symptoms and what could the clinical impact of these findings be? (3:09)
Disclosures: Dr Beatriz Mateos has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In COVID-19
Paul Heath: Novavax Phase 3 Program of Clinical trials evaluating NVX-CoV2373 across the US, South Africa and UK [Part 2]
It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Novavax program of clinical trials evaluating the safety and efficacy of NVX-CoV2373 across the US, South Africa and the UK. Please find Part 1 of this interview available here. To access […]
Paul Heath: Phase 3 trial of Novavax Investigational COVID-19 vaccine [Part 1]
It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Phase III Novavax clinical trial that is investigating the safety and efficacy of NVX-CoV2373, a vaccine candidate for COVID-19. Please find Part 2 of this interview available here. To access more […]
Jeffrey Strich: Phase 2 Trial Results Investigating Fostamatinib for the treatment of COVID-19
It was a great pleasure to meet with Jeffrey Strich (National Institutes of Health Clinical Center, Bethesda, MD, USA) to discuss the findings from a recent phase 2 study investigating fostamatinib for the treatment of hospitalized adults with COVID-19. Useful Resources: Published data available here: Fostamatinib for the treatment of hospitalized adults with COVID-19 A […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!